According to a recent LinkedIn post from Perplexity, the company is forming a Health Advisory Board composed of physicians, researchers, and health technology leaders. The post suggests this group will guide evidence-based product decisions, content quality, and patient-safety considerations for Perplexity’s health-related AI tools.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post emphasizes that Perplexity aims to build AI systems that support clinician–patient relationships rather than replace medical decision-making. For investors, this move may signal a more serious push into regulated or sensitive healthcare-use cases, potentially improving trust, differentiation, and adoption among health systems and enterprise customers.
By foregrounding clinical expertise and safety, the post indicates Perplexity is seeking to mitigate reputational and liability risks associated with inaccurate medical information. If successful, this governance-oriented approach could enhance the company’s positioning against AI competitors in the healthcare information space and support longer-term monetization opportunities tied to professional and institutional users.